 |
Biogen BIIB (news,
chart,
quote) - BIIB volatility Flat as shares sell off on primary endpoint
BIIB is recently down $2.77 to $61.90. DNA and BIIB announced that the phase three EXPLORER study, evaluating Rituzan in Systemic Lupus Erythematosus (SLE) faile |
|
